DiscoverIPO

BlossomHill Therapeutics, Inc.

expected
Aug 6, 2026
status
Expected
proposed ticker
BLSM
Industry
Pharmaceutical Preparations
Headquarters
United States
Incorporated in
DE
Exchange
NASDAQ
Price range
$15.00 – $17.00
Shares offered
7.8M shares
Offer size
$144M
Underwriters
JPM, LEER, GUGGEN, LFSCI, HCWAIN

Overview

Business overview

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small molecule medicines for cancer treatment. The company employs a chemistry-based approach to address unmet medical needs by understanding disease and protein dynamics, utilizing structure-based drug design. Its primary product candidates include BH-30643, an OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer (NSCLC), and BH-30236, a CLK inhibitor for relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company also has a preclinical candidate, BH-501284, targeting activated KRAS mutations.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

  • Deep understanding of disease and protein dynamics
  • Proven track record of developing innovative small molecule medicines
  • Innovative approach to address resistance mutations in cancer treatments

Risk factors

  • Fragmentation of care in EGFR-mutant NSCLC due to existing therapies' limitations
  • Potential for lack of approved therapies for specific mutation resistance
  • Competition from established EGFR TKIs that may develop resistance

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

BlossomHill Therapeutics, Inc.'s offering is currently expected on NASDAQ. The expected date is Aug 6, 2026. Shares are expected to be offered at $15.00 – $17.00, with 7.8M shares on offer, for a total offer size of $144M. The proposed ticker is BLSM. Underwriters on the deal include JPM, LEER, GUGGEN, LFSCI, HCWAIN. BlossomHill Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

BlossomHill Therapeutics, Inc. has filed 3 times, starting with a S1/A on Aug 3, 2026.

Frequently asked questions

When is BlossomHill Therapeutics, Inc. expected to go public?

BlossomHill Therapeutics, Inc. is expected to list on Aug 6, 2026.

What exchange will BlossomHill Therapeutics, Inc. list on?

BlossomHill Therapeutics, Inc. is listing on NASDAQ.

How much is BlossomHill Therapeutics, Inc. raising in its IPO?

BlossomHill Therapeutics, Inc.'s offering is expected to raise $144M.

What is BlossomHill Therapeutics, Inc.'s ticker symbol?

BlossomHill Therapeutics, Inc.'s proposed ticker is BLSM.

Where this data comes from

New York Stock Exchange listings data. Retrieved Aug 3, 2026.

View the original filing on NYSE →

All filings for this company

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.

We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy